Indolent Lymphoma
News
Obinutuzumab trends better than rituxumab in relapsed indolent lymphoma
Key clinical point: Obinutuzumab was associated with a higher overall response rate as compared with rituximab, but obinutuzumab’s clinical...
News
Lenalidomide + rituximab combo effective in recurrent follicular lymphoma
Key clinical point: Lenalidomide combined with rituximab is more active in recurrent follicular lymphoma, compared with lenalidomide monotherapy....
News
Treatment of choice for NLPHL? Involved-field RT alone
Key clinical point: Involved-field radiotherapy alone yields similar survival but fewer toxic effects than do other treatments for stage 1A...
News
Doxorubicin, radiation doses predict heart risk in lymphoma survivors
Key clinical point: Lymphoma survivors treated with autologous hematopoietic stem-cell transplantation (auto-HSC) had a significantly higher risk...
Conference Coverage
Interim PET results guide ongoing therapy in Hodgkin lymphoma
Key clinical point: Bleomycin can be eliminated after two cycles of the ABVD chemotherapeutic regimen based on a negative interim PET scan finding...
News
Interim PET provides limited prognostic value for diffuse large B-cell lymphoma
Key clinical point: After two cycles of standardized, dose-dense chemotherapy in patients with diffuse large B-cell lymphoma (DLBCL), positive...
Conference Coverage
Second pathology review boosts diagnostic accuracy in lymphoma
Key clinical point: A second pathological review of newly-diagnosed lymphoma or suspected lymphoma found discrepancies in 17% of cases. Major...
News
Early relapse signals high mortality in follicular lymphoma
Key clinical point: Patients with follicular lymphoma who relapse within 2 years of receiving R-CHOP are at high risk of death, unlike those who...
Conference Coverage
VIDEO: Rituximab-refractory indolent NHL yields to combo treatment
News
Ibrutinib highly active against refractory Waldenstrom’s macroglobulinemia
Key clinical point: Ibrutinib produced a 90.5% overall response rate and a 73% major response rate in a proof-of-concept trial of 63 patients with...